1 / 9

ASCOT and Steno-2: Aggressive risk reduction benefits two different patient populations

ASCOT and Steno-2: Aggressive risk reduction benefits two different patient populations. Steno-2. ASCOT-LLA. Steno-2: Diabetes + microalbuminuria Intensive target-driven reduction of BP, total-C, TG, A1C vs usual care 7.8 years ASCOT-LLA:

darena
Télécharger la présentation

ASCOT and Steno-2: Aggressive risk reduction benefits two different patient populations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ASCOT and Steno-2: Aggressive risk reduction benefits two different patient populations Steno-2 ASCOT-LLA • Steno-2: • Diabetes + microalbuminuria • Intensive target-driven reduction of BP, total-C, TG, A1C vs usual care • 7.8 years • ASCOT-LLA: • Hypertension + ≥3 CV risk factors, total-C ≤250 mg/dL • Amlodipine/perindopril + atorvastatin vs placebo • 3.5 years Relative risk reduction (%) * † *Composite of CV death, nonfatal MI or stroke, revascularization, and amputation, P < 0.001 †Fatal CHD and nonfatal MI (including silent MI), P < 0.0001 Gaede P et al. N Engl J. Med. 2003;348:383-93. Sever PS et al. Circulation. 2005;112(suppl II):II-134. Abstract 730.

  2. ASCOT: Patients had hypertension and ≥3 other risk factors, fitting a common clinical profile Hypertension Aged ≥55 years Male Microalbuminuria/proteinuria Smoker Family history of CHD Plasma total-C:HDL-C ≥6 Type 2 diabetes Certain ECG abnormalities LVH Prior cerebrovascular events Peripheral vascular disease 0 10 20 30 40 50 60 70 80 90 100 Patients with risk factor (%) Sever PS et al. J Hypertens. 2001;19:1139-47.Sever PS et al. Lancet. 2003;361:1149-58. LVH = left ventricular hypertrophy

  3. ASCOT-BPLA: Reduction in primary outcome (nonfatal MI and fatal CHD) 10 8 RRR = 10% HR = 0.90 (95% CI, 0.79–1.02) P = 0.1052 6 Proportionof events (%) 4 Atenolol-based regimen* 2 Amlodipine-based regimen† 0 0 1 2 3 4 5 6 Time since randomization (years) *Atenolol 50–100 mg ± bendroflumethiazide 1.25–2.5 mg †Amlodipine 5–10 mg ± perindopril 4–8 mg Dahlöf B et al. Lancet. 2005;366:895-906.

  4. ASCOT: Risk reductions with the amlodipine/perindopril regimen Rate/1000 patient-years Amlodipine-based*(n = 9639) Atenolol-based† (n = 9618) <0.05 <0.01 <0.0001 <0.05 0.001 <0.001 NS <0.0001 <0.05 Secondary endpoints Nonfatal MI (excluding silent) 7.4 8.5 + fatal CHD Total coronary endpoint 14.6 16.8 Total CV events and procedures 27.4 32.8 All-cause mortality 13.9 15.5 CV mortality 4.9 6.5 Fatal/nonfatal stroke 6.2 8.1 Fatal/nonfatal HF 2.5 3.0 Tertiary endpoints Development of diabetes 11.0 15.9 Development of renal impairment 7.7 9.1 Amlodipine-based better Atenolol-based better P 0.50 0.75 1.00 1.50 2.00 Unadjusted hazard ratio *Amlodipine 5–10 mg ± perindopril 4–8 mg †Atenolol 50–100 mg ± bendroflumethiazide 1.25–2.5 mg Dahlöf B et al. Lancet. 2005;366:895-906.

  5. CAFE asked whether newer vs older BP treatments have differing effects on central aortic BP N = 2199 5 UK ASCOT centers n = 126Excluded: HR irregularity Poor waveforms N = 2073Evaluable for tonometry n = 1042Amlodipine ± perindopril* n = 1031Atenolol ± bendroflumethiazide† n = 1042 Intent-to-treatn = 1038 Complete information n = 1031 Intent-to-treatn = 1030 Complete information *Newer antihypertensive regimen †Older antihypertensive regimen CAFE Investigators. Circulation. 2006;113:1213-25.

  6. CAFE: Central aortic pressure is lower with the amlodipine/perindopril regimen 140 Brachial SBP 135 130 Central aortic SBP mm Hg 125 120 115 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 Time (years) Amlodipine ± perindoprilAtenolol ± bendroflumethiazide CAFE Investigators. Circulation. 2006;113:1213-25.

  7. CAFE: Lesser ability of β-blockers to reduce augmentation wave P < 0.0001 Atenolol ± bendroflumethiazide Amlodipine ± perindopril CAFE Investigators. Circulation. 2006;113:1213-25.

  8. ASCOT: Lipid lowering is beneficial regardless of baseline cholesterol level Sever PS et al. Lancet. 2003;361:1149-58.

  9. P = 0.015 ASCOT: Greater gain with statin + CCB/ACE inhibitor vs statin + β-blocker/diuretic Fatal CHD and nonfatal MI NS P < 0.0001 NS 10 9.8 9 9 8 7 7.5 Events/1000patient-years 6 5 4 3 4.6 2 - Atorvastatin (+ placebo) 1 0 + Atorvastatin (10 mg) P (interaction between lipid and BP lowering) = 0.025 Atenolol* † Amlodipine Sever PS et al. Circulation. 2005;112(suppl II):II-134. Abstract 730. Sever PS et al. AHA Scientific Sessions. Nov 2005. *Atenolol ± bendroflumethiazide†Amlodipine ± perindopril

More Related